Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cromin-P75
- Development stage
- Unknown
- Lead developer
- Croise Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cromin-P75 is a fixed-dose combination of pregabalin (75 mg) and methylcobalamin (750 mcg) developed by Croise Pharma. It is primarily indicated for the treatment of neuropathic pain, including diabetic neuropathy, postherpetic neuralgia, spinal cord injury pain, and fibromyalgia. Pregabalin is an alpha-2-delta ligand that binds to the auxiliary subunits of voltage-gated calcium channels in the central nervous system, reducing the influx of calcium and subsequent release of excitatory neurotransmitters. Methylcobalamin, a neurologically active form of vitamin B12, acts as a cofactor for methionine synthase, promoting myelin sheath synthesis, nerve fiber protection, and the regeneration of damaged nerve cells. Together, these components work synergistically to alleviate chronic nerve pain and improve nerve conduction.
- Brand names
- Cromin-P75Cromin-P-75Cromin-P 75
- Other names
- Cromin-P75 CapsuleCromin-P-75 CapsuleCromin-P 75 CapsuleCromin-P75 Tab.Cromin-P-75 Tab.Cromin-P 75 Tab.Methylcobalamin + pregabalinPregabalin + methylcobalamin
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (Voltage-gated calcium channel subunit alpha-2/delta-2)MTR (Methionine synthase)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)
Beyond the preview
Go deeper on Cromin-P75.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cromin-P75.